Grant: Fellowship - Priority Announcement: Hepatology
Direct Payment
$50,000.00
Genome-wide Characterization of Liver Pregnane X Receptor Binding Sites and their Role in Interindividual Drug Response
EF 2009-10
Résumé
Adverse reactions to drug treatments constitute a substantial health problem that is estimated to be the fifth leading cause of death globally. Interindividual genetic differences have been shown to play an important causative role in these reactions. One of the major biological culprits for these differences is the drug metabolizing enzyme CYP3A4, present in the liver and intestine. CYP3A4 has been linked to the metabolism of over 50% of prescribed drugs and can vary in its activity as much as 5 to 20 fold between different individuals. The goal of this project is to uncover sequences in the genome that determine CYP3A4 levels in the body following drug treatment, and to determine whether interindividual variation in these sequences can lead to altered drug responses. To uncover these sequences, I plan to take advantage of a state of the art technique termed ChIP-seq. This technique will allow me to generate a map of sequences throughout the whole human genome that regulate CYP3A4 levels following drug induction. These sequences will then be analyzed for their regulatory function using the mouse as a model. The key goal of this project is determine whether human variation within these CYP3A4 regulatory sequences leads to adverse reactions in the clinic. To accomplish this goal, I will look for nucleotide variation within the functional regulatory sequences using previously identified human variants and by sequencing an ethnically diverse population of 1000 individuals that can be called back to the clinic for pharmacological analysis. Potential deleterious variants will be further checked for their effect on regulatory activity using the mouse. These studies will increase our understanding on a genomic scale of how genetic variation in this vital drug response pathway contributes to interindividual differences in drug response and will ultimately lead to more effective treatments.
Programme
Fellowship - Priority Announcement: Hepatology
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
194074
Name
Smith Robin P
Region
California
Country
United States of America
Orgtype
Research Institution
Partnername
The Canadian Association for the Study of Liver
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Genome-wide Characterization of Liver Pregnane X Receptor Binding Sites and their Role in Interindividual Drug Response
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Hepatology
Keyworddelim
Adverse Drug Reactions; Chromatin Immunoprecipitation; Cytochrome P450; Drug Metabolizing Enzymes; Drug Transporters; Gene Regulatory Sequences; Human Nucleotide Variation; Next-Generation Sequencing; Pregnane X Receptor; Tail Vein Injections
Abstract
Adverse reactions to drug treatments constitute a substantial health problem that is estimated to be the fifth leading cause of death globally. Interindividual genetic differences have been shown to play an important causative role in these reactions. One of the major biological culprits for these differences is the drug metabolizing enzyme CYP3A4, present in the liver and intestine. CYP3A4 has been linked to the metabolism of over 50% of prescribed drugs and can vary in its activity as much as 5 to 20 fold between different individuals. The goal of this project is to uncover sequences in the genome that determine CYP3A4 levels in the body following drug treatment, and to determine whether interindividual variation in these sequences can lead to altered drug responses. To uncover these sequences, I plan to take advantage of a state of the art technique termed ChIP-seq. This technique will allow me to generate a map of sequences throughout the whole human genome that regulate CYP3A4 levels following drug induction. These sequences will then be analyzed for their regulatory function using the mouse as a model. The key goal of this project is determine whether human variation within these CYP3A4 regulatory sequences leads to adverse reactions in the clinic. To accomplish this goal, I will look for nucleotide variation within the functional regulatory sequences using previously identified human variants and by sequencing an ethnically diverse population of 1000 individuals that can be called back to the clinic for pharmacological analysis. Potential deleterious variants will be further checked for their effect on regulatory activity using the mouse. These studies will increase our understanding on a genomic scale of how genetic variation in this vital drug response pathway contributes to interindividual differences in drug response and will ultimately lead to more effective treatments.
Competitiondate
200910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Smith, Robin P
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $50,000~ $0~